Gelişmiş Arama

Basit öğe kaydını göster

dc.contributor.authorKaçar, Emine
dc.contributor.authorTan, Fatih
dc.contributor.authorŞahintürk, Serdar
dc.contributor.authorZorlu, Gökhan
dc.contributor.authorSerhatlıoğlu, İhsan
dc.contributor.authorBulmuş, Özgür
dc.contributor.authorErcan, Zübeyde
dc.contributor.authorKeleştimur, Haluk
dc.date.accessioned2024-07-03T10:36:39Z
dc.date.available2024-07-03T10:36:39Z
dc.date.issued2023en_US
dc.identifier.issn0862-8408 / 1802-9973
dc.identifier.urihttps://doi.org/10.33549/physiolres.935064
dc.identifier.urihttps://hdl.handle.net/20.500.12462/14887
dc.descriptionBulmuş, Özgür (Balikesir Author)en_US
dc.description.abstractAgomelatine is a pharmaceutical compound that functions as an agonist for melatonin receptors, with a particular affinity for the MT1 and MT2 receptor subtypes. Its mode of action is integral to the regulation of diverse physiological processes, encompassing the orchestration of circadian rhythms, sleep-wake cycles, and mood modulation. In the present study, we delve into the intricate interplay between agomelatine and the modulation of estrus cycles, gestation periods, offspring numbers, and uterine contractions, shedding light on their collective impact on reproductive physiology. Both in vivo and in vitro experiments were performed. Wistar Albino rats, divided into four groups: two non-pregnant groups (D1 and D2) and two pregnant groups (G1 and G2). The D1 and G1 groups served as control groups, while the D2 and G2 groups received chronic agomelatine administration (10 mg/kg). Uterine contractions were assessed in vitro using myometrial strips. Luzindole, a melatonin receptor antagonist, was employed to investigate the pathway mediating agomelatine's effects on uterine contractions. In in vivo studies, chronic agomelatine administration extended the diestrus phase (p<0.05) in non-pregnant rats, prolonged the gestational period (p<0.01), and increased the fetal count (p<0.01) in pregnant rats. Additionally, agomelatine reduced plasma oxytocin and prostoglandin-E levels (p<0.01) during pregnancy. In vitro experiments showed that agomelatine dose-dependently inhibited spontaneous and oxytocin-induced myometrial contractions. Luzindole (2 mu M) reverse the agomelatine-induced inhibition of myometrial contractions. These findings suggest that agomelatine holds the potential to modulate diverse reproductive parameters during the gestational period, influencing estrus cycling, gestational progression, offspring development, and the orchestration of uterine contractions.en_US
dc.description.sponsorshipFUBAP (Scientific Research Projects Automation) TF.17.39en_US
dc.language.isoengen_US
dc.publisherAcad Sciences Czech Republicen_US
dc.relation.isversionof10.33549/physiolres.935064en_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectAgomelatineen_US
dc.subjectMyometrial Contractionsen_US
dc.subjectGestational Ageen_US
dc.subjectNumber of Offspringen_US
dc.subjectRat Pregnancyen_US
dc.titleModulation of melatonin receptors regulates reproductive physiology: The impact of agomelatine on the estrus cycle, gestation, offspring, and uterine contractions in ratsen_US
dc.typearticleen_US
dc.relation.journalPhysiological Researchen_US
dc.contributor.departmentTıp Fakültesien_US
dc.contributor.authorID0000-0001-7736-402Xen_US
dc.identifier.volume72en_US
dc.identifier.issue6en_US
dc.identifier.startpage793en_US
dc.identifier.endpage807en_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US


Bu öğenin dosyaları:

Thumbnail

Bu öğe aşağıdaki koleksiyon(lar)da görünmektedir.

Basit öğe kaydını göster